Angela C Garinis1,2, Alexandra Cornell3, Gopal Allada4, Kevin P Fennelly5, Ronald J Maggiore2,6,7, Dawn Konrad-Martin1,2. 1. a Department of Otolaryngology - Head and Neck Surgery , Oregon Health & Science University , Portland , OR , USA. 2. b VA Portland Health Care System , VA RR&D Center of Excellence, National Center for Rehabilitative Auditory Research , Portland , OR , USA. 3. c Division of Pulmonary and Critical Care Medicine Adult Cystic Fibrosis Program , Oregon Health & Science University , Portland , OR , USA. 4. d Department of Pediatrics Pulmonary Medicine , Oregon Health & Science University , Portland , OR , USA. 5. e National Heart, Lung and Blood Institute , National Institutes of Health , Bethesda , MD , USA. 6. f Department of Medicine, Hematology & Oncology , Oregon Health & Science University , Portland , OR , USA , and. 7. g Department of Medicine, Hematology & Oncology , University of Rochester , Rochester , NY , USA.
Abstract
OBJECTIVES: Integrating audiological management into the care pathways of clinical specialties that prescribe ototoxic medications for essential, often life-preserving medical care that is critical for early hearing loss identification and remediation. Research shows that successful implementation of a new health service or intervention requires alignment of goals among provider groups, institutional leadership and patients. Thoughtful consideration of the physician's viewpoints about ototoxicity and its implications for treatment planning is, therefore, important for the implementation and enduring success of an ototoxicity monitoring programme (OMP). DESIGN: This discussion paper uses qualitative methods to explore the perspectives of four physicians on OMP provision in their patient populations. STUDY SAMPLE: Three pulmonologists and one oncologist completed the written survey or survey-based interview described in this report. RESULTS: Each physician indicated that (i) ototoxicity is a potential problem for their patients; (ii) monitoring hearing is important to ensure good quality of life among their patients and (iii) treatment modification would be considered if an alternative treatment option were available. The physicians differed in their approaches to ototoxicity monitoring, from routine referrals to audiology, to relying on patient self-referral. CONCLUSION: Physician provider input is needed to optimise monitoring schedules and OMP care coordination with audiology.
OBJECTIVES: Integrating audiological management into the care pathways of clinical specialties that prescribe ototoxic medications for essential, often life-preserving medical care that is critical for early hearing loss identification and remediation. Research shows that successful implementation of a new health service or intervention requires alignment of goals among provider groups, institutional leadership and patients. Thoughtful consideration of the physician's viewpoints about ototoxicity and its implications for treatment planning is, therefore, important for the implementation and enduring success of an ototoxicity monitoring programme (OMP). DESIGN: This discussion paper uses qualitative methods to explore the perspectives of four physicians on OMP provision in their patient populations. STUDY SAMPLE: Three pulmonologists and one oncologist completed the written survey or survey-based interview described in this report. RESULTS: Each physician indicated that (i) ototoxicity is a potential problem for their patients; (ii) monitoring hearing is important to ensure good quality of life among their patients and (iii) treatment modification would be considered if an alternative treatment option were available. The physicians differed in their approaches to ototoxicity monitoring, from routine referrals to audiology, to relying on patient self-referral. CONCLUSION: Physician provider input is needed to optimise monitoring schedules and OMP care coordination with audiology.
Entities:
Keywords:
Ototoxicity monitoring; adult or general hearing screening; aminoglycoside; chemotherapy; cisplatin; medical audiology; oncology; pulmonology
Authors: Angela C Garinis; Gayla L Poling; Ronald C Rubenstein; Dawn Konrad-Martin; Timothy E Hullar; David M Baguley; Holly L Burrows; Jennifer A Chisholm; Amy Custer; Laura Dreisbach Hawe; Lisa L Hunter; Theodore K Marras; Candice E Ortiz; Lucretia Petersen; Peter S Steyger; Kevin Winthrop; Erika M Zettner; Khaya Clark; Michelle Hungerford; Jay J Vachhani; Carmen C Brewer Journal: Am J Audiol Date: 2021-09-22 Impact factor: 1.636
Authors: Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille Journal: Int J Audiol Date: 2017-11-20 Impact factor: 2.117
Authors: Chelsea M Blankenship; Lisa L Hunter; M Patrick Feeney; Madison Cox; Lindsey Bittinger; Angela C Garinis; Li Lin; Gary McPhail; John P Clancy Journal: Am J Audiol Date: 2021-01-19 Impact factor: 1.636